ASX ANNOUNCEMENT Lumos Diagnostics Annual General Meeting Chair’s Address MELBOURNE, Australia (13 November 2026) – Lumos Diagnostics Holdings Ltd (ASX: LDX, “Lumos” or the “Company”), a leader in rapid, point-of-care diagnostic technologies, today releases it’s Chair’s Address for...
AGM Chair Address
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Lumos Diagnostics Holdings Ltd. has released the Chair's Address for its Annual General Meeting, highlighting significant achievements in the past year. The address emphasizes the receipt of FDA CLIA waiver clearance for the FebriDx test, which greatly expands the company's market opportunity in the U.S. Additionally, the company is building a commercial framework to enhance shareholder value and has made progress in expanding reimbursement coverage for its products. Looking ahead, Lumos aims to drive adoption of FebriDx, expand its services business, and deepen partnerships while maintaining a disciplined approach to capital allocation.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
On 6ix: 6ix.com/news/agm-chair-address-3
Release
Lumos Diagnostics Holdings Ltd. on 6ix
In the deck
Earlier from Lumos Diagnostics
- Lumos Expands FebriDx Adoption Across WellStreet Locations
- Investor Presentation
- Quarterly Activities/Appendix 4C Cash Flow Report
- Application for quotation of securities - LDX
- Q1 FY27 Quarterly Results Date & Webinar Invitation
Later from Lumos Diagnostics
- 2026 AGM Presentation
- Results of Annual General Meeting
- Lumos Secures Distribution for FebriDx in Portugal
Follow Lumos Diagnostics into a list and get an email when it puts out news.
Follow Lumos Diagnostics